Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fire sale!
Well…he did like he said and dropped the news. New direction is good. Can’t wait for more details.
I think so too.
Metaverse.
I think this is the part of the story where “fear of missing out” aka. FOMO , begins to set in.
Good catch. That’s very interesting! Wonder how long it takes to update status on otc website?
Yeah, they just pr’d same news as in 8-k. Bigger audience.
Big spike!
From the filing, it appears they’re raising money. For what, we don’t know yet, but most likely debt reduction and/or acquisitions.
Looking like we are in the midst of a short term trend reversal here. Long term upward trend still intact.
I can see people panicking, but I’m just gonna hunker down on this one and trust the process. I think big things are coming here.
Prolly one of the least expensive Metaverse stocks out there. Lots of potential to say the least.
Oh my bad, that 200 million was issued within 1 year prior to filing. Well, it takes money to make money. This will be good for acquisitions. I’m invested here and am looking forward to seeing what Glenn has in store for us.
I read 200 million. That’s not much. Did I read that incorrectly?
MM’s still manipulating here. Just smacked the ask for 500k and they filled me at .00285
Great news!
Solid day! This company is gonna take a lot of market share from competitors this year and next!
One more I think to high 1’s low 2’s. You will know when to add because clowns will be in full circus mode! Tell tale sign.
I’m not greedy. Just looking for $3-5 in the initial stages here. You can swing for the fences if you want to, but time is money and that may take a few more years. Just being honest with you. Hate to see you get your hopes up too high. GL! Go RGBP!
Lol. Can’t say you’re not entertaining.
Interesting that there are so many Market Makers on this ticker. It’s got as many as a Nasdaq or NYSE stock. Most otc’s will have 4 or 5. This one has at minimum 13. Why is that? Hmmm…
Great news this morning! Glenn is bringing big time value to this ticker. Can’t wait to see what the next updates are.
Yes, patience is definitely a virtue. Will pay big dividends here.
Yeah, I think we’re one good news release away from a complete trend reversal. We’ll see what’s the scope of work assessment thats due today says and also where the the IND renewals are at that were initiated more than 60 days ago. Could be uplisting news as well. Lots of positive catalysts incoming here.
Getting ready to pop. Make sure you have shares everyone. Gonna be a fun ride!
Yup. Once people realize the scarcity of shares and the value here, this will be a 10x gainer in short order.
Few remaining flippers to churn out before we ascend in earnest. Won’t be long now.
Pressure building. Folks beginning to understand the magnitude of this latest 8-k.
Here is another good one with Dr. Rafii. Here he talks about growing blood vessels and endothelial cells. He says the endothelial cells are like magic bullets they can custom design for tumors and trick the tumors to stop growing. All of this customized work done invitro so less biopsies are needed.
Wow! What a plethora of information about NR2F6! Such a rabbit hole. Seems like it’s now being researched the World over and our little company owns the patents for it. Double wow!
Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6
Victoria Klepsch et al. Cancers (Basel). 2021.
Free PMC article
Hide details
Cancers (Basel)
. 2021 May 26;13(11):2600.
doi: 10.3390/cancers13112600.
Authors
Victoria Klepsch 1 , Kerstin Siegmund 1 , Gottfried Baier 1
Affiliation
1 Institute for Translational Cell Genetics, Medical University Innsbruck, 6020 Innsbruck, Austria.
PMID: 34073258
PMCID: PMC8197903
DOI: 10.3390/cancers13112600
Full text links
Cite
Abstract
Additional therapeutic targets suitable for boosting anti-tumor effector responses have been found inside effector CD4+ and CD8+ T cells. It is likely that future treatment options will combine surface receptor and intracellular protein targets. Utilizing germline gene ablation as well as CRISPR/Cas9-mediated acute gene mutagenesis, the nuclear receptor NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) has been firmly characterized as such an intracellular immune checkpoint in effector T cells. Targeting this receptor appears to be a strategy for improving anti-tumor immunotherapy responses, especially in combination with CTLA-4 and PD-1. Current preclinical experimental knowledge firmly validates the immune checkpoint function of NR2F6 in murine tumor models, which provides a promising perspective for immunotherapy regimens in humans in the near future. While the clinical focus remains on the B7/CD28 family members, protein candidate targets such as NR2F6 are now being investigated in laboratories around the world and in R&D companies. Such an alternative therapeutic approach, if demonstrated to be successful, could supplement the existing therapeutic models and significantly increase response rates of cancer patients and/or expand the reach of immune therapy regimens to include a wider range of cancer entities. In this perspective review, the role of NR2F6 as an emerging and druggable target in immuno-oncology research will be discussed, with special emphasis on the unique potential of NR2F6 and its critical and non-redundant role in both immune and tumor cells.
Keywords: NR2F6 inhibition as first-in-class cancer immunotherapy concept; alternative and druggable cancer immune checkpoint; orphan nuclear receptor NR2F6; transcriptional repressor of CD4+ and CD8+ effector but not regulatory T cell functions; tumor immunology; tumor-promoting function.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Figure 1
Figure 1 The dual role of NR2F6…
Figure 2
Figure 2 NR2F6 is the distantly related…
Figure 3
Figure 3 NR2F6 dimerization and mechanism of…
Amazing! What a read!! Thanks for sharing.
Thanks! Great to be here and great board. Enjoy the day!
The drop on Friday was fear of how they were gonna come up with $50 million not to mention whatever the value of Canary Controlling Interest will be. I still think the share price will rise organically now that this news has had a chance to sink in and people are beginning to see the path forward and the caliber of the players involved. We’ve been one of the most posted boards this weekend if that gives us a sense of how big this news is. Once the pps averages 15 cents, which I honestly don’t expect to be too much longer, Koos could use the remaining authorized shares which at that price would equate to $50M, but it’s now seeming more likely that there is a large player behind the scenes that will enable that transaction. As someone posted on this board, there was an approximate amount of $50 million worth of shares sold by Eli Lilly recently earlier this month coincidently and the initial down payment for the Curevac deal was also $50 Million. Things that make you go hmmm… So it seems to me that RGBP will just be on the hook, initially anyway, for the common shares that represent Canary Controlling Interest and the $1,000,000. So how much is CCI gonna be worth is the question and will RGBP have enough authorized commons to complete the transaction? I guess it all depends on what the share price will be. With the upcoming catalysts, I suspect we will need far less commons than what we would need at this share pride. Just my opinion though. Getting extremely interesting around here to say the least. Go RGBP!!
I also find it very interesting that the upfront payment to Curevac was $50M. How much do we need at the closing with Canary? $50M? Still speculative of course, but patterns are definitely beginning to develop for those with the eyes to see them.
Interesting. Any idea who would be the closest competition to RGBP, that has these checkpoint inhibitors in patent lockdown like we do? I’m just thinking, are there any other good alternatives to RGBP in regards to this mRNA science for Big Pharma to consider, or must all paths for this science lead through RGBP and Cornell? Are there other checkpoints besides NR2F6 that would give similar results? I’m feeling like our research is unmatched in this realm and now with Cornell’s vascular endothelial research with tumors it’s a forgone conclusion that we are literally the Diamond in the rough that everyone has been looking for. Seems we were way ahead of the curve in 2016 and overlooked, but the entire field has been turned upside down due to covid and now everyone is flush with cash and scrambling to gain the edge. Lilly makes the most sense here though due to prior connections and the fact that prior jaunts into this wilderness have been unsuccessful. Thoughts?
Even though on paper we’re paying for BRG assessment, I think hiring them was more for the benefit of Canary and whom ever is behind the scenes funding this entire thing. I mean, if an entity is dropping $50 million, what’s $25k to make sure everything is on the up and up? Surely doesn’t hurt either to pay a company with inroads to the FDA to make sure the IND apps get processed with no hiccups. This is how legitimate business is done.
Wow! Is that why they became current, getting their IP approved, paying off all debt, settling lawsuits, resubmitting IND’s for clinical trials and bringing Cornell IP into company? And not to mention why Koos stated in a previous 8-k that he believes things coming here will DWARF anything the company has seen previously? Hmmm…you may be onto something with that Lily thought. Excellent dot connecting!
9. Intellectual Property
It is understood that the IP that will be licensed into Canary will originate from Cornell University and specifically from the laboratory of Dr. Shahin Rafii. The final IP will be included in the definitive agreement as an appendix. This IP allows for the creation of patient-derived tumor on vascular nets for in vitro testing of therapeutic agents.
Start at 18:10 to see our guy, Dr. Shahin Rafii.